Skip to main content
Premium Trial:

Request an Annual Quote

Diversa Awarded $3.2M from NIH for Biodefense Antibody Optimization

NEW YORK, July 25 - Diversa, a San Diego-based microbial genomics firm, announced today that the National Institute of Allergy and Infectious Diseases was prepared to award the company approximately $3.2 million to optimize three antibodies that the U.S. army is already using for the detection of bioterrorism agents.

 

The antibodies in question were developed to detect ricin toxin, plague, and alpha-virus. The company will use the money to employ its Gene Site Saturation Mutagenesis technologies to optimize the binding characteristics of the antibodies. The goal is to increase the diagnostic sensitivity and selectivity of the three antibodies being used now as well as to develop ways to improve other biodefense diagnostics.

 

The NIAID has authorized $890,000 for the first six months of the project.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.